Study #2020-1324
Phase 1, multi-center, open-label study of VT3989, alone or in combination, in patients with refractory locally advanced or metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
VT3989, Nivolumab & Ipilimumab, Osimertinib
Description
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in 3- or 4-week cycles in patients with mesothelioma and/or metastatic solid tumors that are resistant or refractory to standard therapy or for which no effective standard therapy is available.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Adult, Mesothelioma, NSCLC
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-833-997-2081
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.